SkinHealth’s SkinStylus Gains FDA Clearance for Periorbital Wrinkles Across All Skin Types
SKIN•SkinHealth Systems won FDA clearance for its SkinStylus device to improve periorbital wrinkles in adults 22+ across all Fitzpatrick types, making it the sole microneedling system cleared for facial acne and abdominal scars. U.S. microneedling spend jumped 33% to $330 million in 2025, supporting adoption of SkinStylus alongside Hydrafacial treatments.
1. Expanded FDA Clearance
On July 7, SkinHealth Systems announced that the FDA cleared its SkinStylus SteriLock MicroSystem for improvement of periorbital wrinkles in adults 22 years and older across all Fitzpatrick skin types. This expands its clinically supported indications, joining existing approvals for facial acne scars in skin types I–III and hypertrophic abdominal scars.
2. Market Growth Accelerates Microneedling Adoption
In 2025, consumer spend on microneedling in U.S. medical aesthetic practices rose 33% year-over-year to approximately $330 million, reflecting growing demand for minimally invasive skin-quality treatments. Hydrafacial pairing drove adoption, with one in five Hydrafacial consumers receiving microneedling and 90% expressing future interest in combination protocols.
3. Unique Competitive Position
With the new periorbital wrinkle indication, SkinStylus becomes the only microneedling device cleared for three distinct uses—facial acne scars, periorbital wrinkles and abdominal scars—strengthening its differentiation in the microneedling market. This positions SkinHealth Systems to capture market share as providers seek versatile, clinically validated devices.
4. Strategic Ecosystem and Growth Outlook
SkinStylus integrates within the broader Hydrafacial professional ecosystem, supporting the company’s strategy of science-backed innovation and platform expansion. The expanded clearance could drive device placements, consumable sales and service revenues as medical practices adopt combination protocols to meet rising consumer demand.
